Neuphoria Therapeutics Inc. Files Q3 2025 10-Q

Ticker: NEUP · Form: 10-Q · Filed: May 20, 2025 · CIK: 1191070

Neuphoria Therapeutics Inc. 10-Q Filing Summary
FieldDetail
CompanyNeuphoria Therapeutics Inc. (NEUP)
Form Type10-Q
Filed DateMay 20, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, pharmaceuticals, financial-reporting

TL;DR

Neuphoria Therapeutics filed its 10-Q for Q3 2025, showing financial updates and historical data.

AI Summary

Neuphoria Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Bionomics Limited, is in the pharmaceutical preparations sector. Key financial reporting periods include Q3 2025 and the fiscal year ending June 30, 2025. The filing also references events and financial data from 2021 through 2024, including details on equity incentive plans and warrants.

Why It Matters

This filing provides investors with an update on Neuphoria Therapeutics' financial health and operational status for the third quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Neuphoria Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

  • Q3 2025 — Quarterly Period (Reporting period for this 10-Q filing.)
  • 0630 — Fiscal Year End (Indicates the end of the company's fiscal year.)

Key Players & Entities

  • Neuphoria Therapeutics Inc. (company) — Filer
  • BIONOMICS LIMITED/FI (company) — Former Company Name
  • 20250331 (date) — Period of Report
  • 0630 (date) — Fiscal Year End
  • 781-439-5551 (phone_number) — Business Phone

FAQ

What is the primary business of Neuphoria Therapeutics Inc.?

Neuphoria Therapeutics Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

When was Neuphoria Therapeutics Inc. formerly known as?

Neuphoria Therapeutics Inc. was formerly known as BIONOMICS LIMITED/FI, with a date of name change on 20020920.

What is the reporting period for this 10-Q filing?

The conformed period of report for this 10-Q filing is 20250331, representing the quarter ending March 31, 2025.

Where is Neuphoria Therapeutics Inc. located?

Neuphoria Therapeutics Inc. is located at 100 Summit Dr, Burlington, MA 01803.

What are some of the financial reporting dates mentioned in the filing?

The filing references several dates including 2025-03-31, 2024-12-24, 2024-07-01, 2025-01-01, 2024-12-31, 2021-06-30, 2023-10-01, 2023-12-31, 2025-04-16, 2024-10-01, 2024-06-30, 2024-07-01, 2025-03-31, 2024-12-31, and 2023-09-30.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 20, 2025 regarding Neuphoria Therapeutics Inc. (NEUP).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.